You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 17, 2025

Alk Abello Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Alk Abello
International Patents:150
US Patents:8
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Alk Abello

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Alk Abello OTIPRIO ciprofloxacin INJECTABLE, SUSPENSION;OTIC 207986-001 Dec 10, 2015 DISCN Yes No 9,220,796 ⤷  Try for Free Y ⤷  Try for Free
Alk Abello OTIPRIO ciprofloxacin INJECTABLE, SUSPENSION;OTIC 207986-001 Dec 10, 2015 DISCN Yes No 11,246,863 ⤷  Try for Free Y ⤷  Try for Free
Alk Abello OTIPRIO ciprofloxacin INJECTABLE, SUSPENSION;OTIC 207986-001 Dec 10, 2015 DISCN Yes No 11,040,004 ⤷  Try for Free ⤷  Try for Free
Alk Abello OTIPRIO ciprofloxacin INJECTABLE, SUSPENSION;OTIC 207986-001 Dec 10, 2015 DISCN Yes No 9,205,048 ⤷  Try for Free ⤷  Try for Free
Alk Abello OTIPRIO ciprofloxacin INJECTABLE, SUSPENSION;OTIC 207986-001 Dec 10, 2015 DISCN Yes No 11,369,566 ⤷  Try for Free Y ⤷  Try for Free
Alk Abello OTIPRIO ciprofloxacin INJECTABLE, SUSPENSION;OTIC 207986-001 Dec 10, 2015 DISCN Yes No 9,233,068 ⤷  Try for Free Y ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for Alk Abello Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1429780 132013902137451 Italy ⤷  Try for Free PRODUCT NAME: CIPROFLOXACINA E DESAMETASONE(CILODEX); AUTHORISATION NUMBER(S) AND DATE(S): 48976, 20120810;041182015/M, 20121106
1429780 122012000070 Germany ⤷  Try for Free PRODUCT NAME: KOMBINATION AUS CIPROFLOXACIN UND DEXAMETHASON, INSBESONDERE CIPROFLOXACINHYDROCHLORID UND DEXAMETHASON; NAT. REGISTRATION NO/DATE: 85150.00. 00 20120830; FIRST REGISTRATION: DAENEMARK 48976 20120808
1429780 SPC/GB12/058 United Kingdom ⤷  Try for Free PRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003
1429780 13C0012 France ⤷  Try for Free PRODUCT NAME: COMBINAISON DE CIPROFLOXACINE ET DE DEXAMETHASONE, EN PARTICULIER DE CHLORHYDRATE DE CIPROFLOXACINE ET DE DEXAMETHASONE; NAT. REGISTRATION NO/DATE: NL 41308 20121214; FIRST REGISTRATION: 48976 20120808
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Pharmaceutical Competitive Landscape Analysis: ALK-Abelló – Market Position, Strengths & Strategic Insights

In the ever-evolving pharmaceutical industry, ALK-Abelló stands out as a specialized player focusing on allergy immunotherapy. This comprehensive analysis delves into ALK-Abelló's market position, strengths, and strategic insights, providing valuable information for industry professionals and investors alike.

Company Overview

ALK-Abelló A/S, commonly known as ALK, is a Denmark-based pharmaceutical company with a rich history dating back to 1923[1]. The company specializes in the development and manufacturing of allergy immunotherapy (AIT) products for the prevention and treatment of allergies[1]. With a global presence in 46 countries and a workforce of approximately 2,900 employees, ALK has established itself as a leader in the allergy treatment market[1][2].

Market Position

Global Market Share

ALK-Abelló commands a significant 35% global market share in the allergy immunotherapy sector, solidifying its position as the market leader[2]. This dominant position provides the company with a strong foundation for future growth and expansion.

Geographic Presence

The company's operations span across multiple continents, with a strong focus on Europe, North America, and Asia. ALK generates 67% of its revenue from sales in Europe, indicating a strong foothold in its home market[1].

"ALK-Abelló is the market leader in its field, with a 35% global market share. Just 1% of its 500m strong target market is using these therapies yet, which leaves massive potential for growth." - Undervalued Shares[2]

Product Portfolio

ALK's product range encompasses three main categories of allergy immunotherapy products, accounting for 88% of the company's revenues[1]:

  1. Sublingual immunotherapy tablets (SLIT-tablets)
  2. Sublingual immunotherapy drops (SLIT-drops)
  3. Subcutaneous immunotherapy (SCIT)

The company also offers additional products such as emergency adrenaline autoinjectors and allergy diagnostic kits[1].

Strengths and Competitive Advantages

Research and Development Expertise

ALK-Abelló's century-long history in allergy research has resulted in significant expertise and innovation in the field. The company's main research and development center, located in Hørsholm, Denmark, continues to drive advancements in allergy treatment[1].

Diverse Product Portfolio

The company's wide range of allergy immunotherapy products, covering various administration methods and allergens, provides a competitive edge. This diversity allows ALK to cater to different patient needs and preferences.

Strong Market Leadership

As the global market leader with a 35% share, ALK-Abelló benefits from economies of scale, brand recognition, and a strong negotiating position with suppliers and partners[2].

Established Distribution Network

ALK's presence in 46 countries, either directly or through partnerships, ensures a robust distribution network for its products[1]. This global reach allows the company to tap into various markets and adapt to regional needs.

Strategic Insights

Focus on Sublingual Immunotherapy

ALK-Abelló has been strategically focusing on the development and commercialization of sublingual immunotherapy tablets (SLIT-tablets). This emphasis aligns with the growing preference for non-invasive treatment options among patients and healthcare providers.

Expansion into Food Allergies

In 2021, ALK announced its entry into food allergy treatment, beginning with the development of a tablet for peanut allergies[1]. This strategic move opens up new market opportunities and addresses a significant unmet medical need.

Digital Health Initiatives

The company has launched a sister brand, klarify.me, offering a range of pre-screened products and services to help people manage their allergies[1]. This digital health initiative demonstrates ALK's commitment to providing comprehensive allergy management solutions beyond traditional pharmaceuticals.

Financial Performance and Outlook

Recent Financial Results

In 2023, ALK-Abelló delivered strong financial results:

  • Revenue increased by 10% to DKK 1,345 million
  • EBITDA grew by 50% to DKK 187 million
  • Free cash flow improved by DKK 307 million[5]

Future Projections

ALK-Abelló has set ambitious financial targets for the coming years:

  • 10% annual sales growth target
  • EBIT margin target of 25% by 2025[2]

Analysts project continued growth, with SEB Equity Research estimating an EBIT margin of 19.4% in 2024 and 23.6% in 2025[2].

Market Trends and Opportunities

Growing Allergy Prevalence

The increasing prevalence of allergies worldwide presents a significant growth opportunity for ALK-Abelló. With only 1% of the 500 million strong target market currently using allergy immunotherapy, there is substantial room for market expansion[2].

Shift Towards Personalized Medicine

The trend towards personalized medicine in healthcare aligns well with ALK's focus on targeted allergy treatments. This shift may drive increased adoption of the company's products and services.

Technological Advancements

Ongoing advancements in diagnostic technologies and treatment delivery methods present opportunities for ALK to innovate and improve its product offerings.

Challenges and Risks

Market Competition

While ALK-Abelló holds a leading position, the company faces competition from other pharmaceutical firms entering the allergy treatment market. Maintaining market share and differentiating its products will be crucial.

Regulatory Environment

As with all pharmaceutical companies, ALK is subject to stringent regulatory requirements. Changes in regulations or delays in product approvals could impact the company's growth trajectory.

Economic Factors

Global economic conditions, including healthcare spending trends and reimbursement policies, may affect the demand for ALK's products.

Competitive Landscape

Key Competitors

ALK-Abelló operates in a competitive landscape that includes other specialized allergy treatment companies and larger pharmaceutical firms. Some notable competitors include:

  1. Allergy Therapeutics Plc
  2. Allergopharma GmbH & Co KG
  3. Biomay AG
  4. Stallergenes Greer Ltd[4]

Comparative Analysis

When compared to its competitors, ALK-Abelló stands out in several areas:

  • Market Leadership: With its 35% global market share, ALK-Abelló maintains a dominant position in the allergy immunotherapy sector[2].
  • Product Range: The company's diverse portfolio of SLIT-tablets, SLIT-drops, and SCIT products provides a competitive advantage[1].
  • Geographic Reach: ALK's presence in 46 countries surpasses many of its competitors, allowing for broader market access[1].

Future Outlook and Strategic Direction

New Growth Strategy

In June 2024, ALK-Abelló launched a new corporate strategy called "Allergy +" with financial ambitions set for 2028. The strategy aims to:

  1. Strengthen leadership in allergy immunotherapy
  2. Establish a leading position in food allergy and anaphylaxis
  3. Pursue innovations in adjacent allergic conditions with high unmet needs[8]

Expansion into New Markets

ALK-Abelló continues to explore opportunities for geographic expansion, particularly in emerging markets with growing allergy prevalence.

Investment in R&D

The company remains committed to investing in research and development to maintain its innovative edge and expand its product pipeline.

Digital Transformation

ALK-Abelló is likely to continue its digital health initiatives, leveraging technology to enhance patient care and create new revenue streams.

Key Takeaways

  1. ALK-Abelló is the global market leader in allergy immunotherapy with a 35% market share.
  2. The company's diverse product portfolio and strong R&D capabilities provide a competitive advantage.
  3. ALK-Abelló has demonstrated strong financial performance, with ambitious growth targets for the future.
  4. The company's new "Allergy +" strategy focuses on strengthening its core business while expanding into new areas like food allergies.
  5. Significant market potential exists, with only 1% of the target market currently using allergy immunotherapy products.
  6. ALK-Abelló faces challenges from market competition and regulatory environments but is well-positioned for future growth.

FAQs

  1. What is ALK-Abelló's primary focus in the pharmaceutical industry? ALK-Abelló primarily focuses on the development and manufacturing of allergy immunotherapy products for the prevention and treatment of allergies.

  2. How does ALK-Abelló's market share compare to its competitors? ALK-Abelló holds a dominant 35% global market share in the allergy immunotherapy sector, positioning it as the market leader.

  3. What are the main types of products offered by ALK-Abelló? The company's main product categories include sublingual immunotherapy tablets (SLIT-tablets), sublingual immunotherapy drops (SLIT-drops), and subcutaneous immunotherapy (SCIT) products.

  4. What is ALK-Abelló's new growth strategy called? ALK-Abelló's new growth strategy is called "Allergy +", which aims to strengthen its leadership in allergy immunotherapy and expand into new areas such as food allergies.

  5. What percentage of ALK-Abelló's target market currently uses allergy immunotherapy products? Currently, only 1% of ALK-Abelló's 500 million strong target market is using allergy immunotherapy products, indicating significant potential for market growth.

Sources cited: [1] https://en.wikipedia.org/wiki/ALK-Abell%C3%B3 [2] https://www.undervalued-shares.com/weekly-dispatches/alk-abello-denmarks-next-pharma-highflyer/ [4] https://www.globaldata.com/company-profile/alk-abello-as/ [5] https://ir.alk.net/news-releases/news-release-details/annual-report-2023-alk-delivers-9-sales-growth-profits-50 [8] https://ir.alk.net/news-releases/news-release-details/alk-launches-new-growth-strategy-and-2028-financial-ambitions

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.